acecainide has been researched along with disopyramide in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (42.86) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akazawa, M; Inui, K; Masuda, S; Okuda, M; Saito, H; Urakami, Y | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Garthwaite, SM; Hackett, AM; McDonald, SJ; Schneider, P; Schweingruber, F | 1 |
| Roden, DM | 1 |
| Lalka, D; McNamara, PJ; Pieper, JA; Slaughter, RL; Wyman, MG | 1 |
| Lasky, FD; Wesley, JF | 1 |
| Howanitz, JH; Howanitz, PJ | 1 |
| Mohiuddin, SM; Ross, WB | 1 |
| Roden, DM; Woosley, RL | 1 |
2 review(s) available for acecainide and disopyramide
| Article | Year |
|---|---|
Antiarrhythmic drug monitoring.
Topics: Acecainide; Anti-Arrhythmia Agents; Disopyramide; Humans; Lidocaine; Phenytoin; Procainamide; Propranolol; Quinidine | 1981 |
Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide.
Topics: Acecainide; Animals; Anti-Arrhythmia Agents; Disopyramide; Drug Interactions; Electrocardiography; Electrophysiology; Humans; Kinetics; Procainamide; Quinidine | 1983 |
12 other study(ies) available for acecainide and disopyramide
| Article | Year |
|---|---|
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
Topics: Animals; Cell Line; Dogs; Kidney; Kidney Tubules; Kinetics; Membranes; Nephrons; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Rats; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Substrate Specificity; Tetraethylammonium; Transfection | 2001 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Simple in vitro method to characterize antiarrhythmic agents.
Topics: Acecainide; Animals; Anti-Arrhythmia Agents; Disopyramide; Electric Stimulation; Guinea Pigs; In Vitro Techniques; Myocardial Contraction; Papillary Muscles; Quaternary Ammonium Compounds; Refractory Period, Electrophysiological; Sotalol; Verapamil | 1990 |
Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Delayed-Action Preparations; Disopyramide; Heart Arrest; Humans; Lidocaine; Mexiletine; Myocardial Infarction; Procainamide; Resuscitation; Tocainide | 1985 |
Factors influencing serum protein binding of lidocaine in humans.
Topics: Acecainide; Blood Proteins; Bupivacaine; Disopyramide; Humans; Lidocaine; Orosomucoid; Procainamide; Propranolol; Protein Binding; Quinidine; Serum Albumin | 1981 |
High performance liquid chromatographic analysis of the antiarrhythmic drugs procainamide, disopyramide, quinidine, propranolol and metabolites from serum extracts.
Topics: Acecainide; Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Disopyramide; Humans; Procainamide; Propranolol; Pyridines; Quinidine; Spectrophotometry, Ultraviolet | 1981 |
Antiarrhythmic therapy: new additions and future expectations.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Bretylium Tosylate; Disopyramide; Encainide; Humans; Lidocaine; Mexiletine; Tocainide; Verapamil | 1983 |